An interventional study of bronchial fibroscopy in Pulmonary Disease, Chronic Obstructive, sponsored by University Hospital, Montpellier. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-12.
Sponsored by University Hospital, Montpellier · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Pulmonary Disease, Chronic Obstructive by University Hospital, Montpellier — 2 open to participants now, 2 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · University Hospital, Montpellier.
Among the 18 studies in Pulmonary Disease, Chronic Obstructive by University Hospital, Montpellier, this one is the 6th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2025, is one of 9 with no phase, and was the 18th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →2 of the 18 studies in Pulmonary Disease, Chronic Obstructive by University Hospital, Montpellier are open now, in 1 country. Recruiting first, the newest first:
University Hospital, Montpellier · Sites in France
Ages 40–85
By country, each count listing its studies:
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 50 across the 11 interventional studies, 30 across the 7 observational. Of the 15 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Hospital, Montpellier is the lead sponsor of 1,264 studies on the registry; 226 are open to participants now.
1 of the studies in Pulmonary Disease, Chronic Obstructive by University Hospital, Montpellier that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04339270University Hospital, MontpellierChronic Airway Disease, Mucus Rheology and Exacerbations | 2027-02 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies in Pulmonary Disease, Chronic Obstructive by University Hospital, Montpellier, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this interventional, cross-sectional and pathophysiological experimental study is to evaluate the potential of a patient's induced pluripotent stem (iPS) cells, used prior to the re-differentiation stage, to enable ex vivo repair of the injured epithelium in patients with chronic obstructive pulmonary disease (COPD), smokers without COPD and non-smoking controls.
The main questions it aims to answer are:
Researchers will compare 3 groups of participants (COPD patients, smokers without COPD and non-smokers without COPD) for epithelial repair efficacy between non-grafted ALI cultures and ALI cultures grafted with iPS cells, in order to assess their contribution to epithelial repair.
Participants will undergo a bronchial fibroscopy (for clinical indications) with two additional biopsies specific to the study.
This research could lead to breakthroughs in cell-based therapies for COPD, with long-term implications for epigenetic treatments and in vivo applications.
Recently, the research team were able to show that there is a deficiency in a particular subtype of club cells destined to become ciliated in COPD, which would explain the inversion of the ciliated cell/caliciform cell ratio and therefore in the formation of the mucous plugs involved in bronchiolar obstruction.
iPS (induced pluripotent stem cells) represent a major biological breakthrough that has been awarded a Nobel Prize. They offer the advantage of being pluripotent, capable of multiplying endlessly, and thus of differentiating into any other cell type, or even organ, in short, embryogenesis. Researchers have developed a protocol for differentiating iPS cells into bronchial epithelia, with interesting success. These epithelia reconstituted in an air-liquid interface (iALI) reproduce all the characteristics of epithelia in vivo, in particular with the presence of all cell subtypes.
The research team hypothesizes that a patient's iPS cells, used before the re-differentiation stage, will enable ex vivo repair of his damaged epithelium.
The expected results of this project will be to validate the in vitro model of epithelial cell aggression in air-liquid interface (ALI) cultures, and to determine the feasibility of seeding iPS-derived epithelial cells. ALI epithelia from COPD patients would repair better or even normally thanks to iPS.
Ultimately, this project could be a potential therapy targeting epigenetics, and why not a cell therapy.
General Inclusion Criteria
Group 1 Inclusion Criteria:
Group 2 Inclusion Criteria: Smokers without COPD (n=10)
Group 3 Inclusion Criteria: Non-smoker controls (n=10)
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bronchial biopsy performed during a planned bronchial fibroscopy as part of their disease management.
Procedure: bronchial fibroscopy
Bronchial biopsy performed during a planned bronchial fibroscopy as part of their disease management.
Procedure: bronchial fibroscopy
Bronchial biopsy performed during a planned bronchial fibroscopy as part of their disease management.
Procedure: bronchial fibroscopy
2 bronchial biopsies will be taken during bronchial fibroscopy
The main objective is to evaluate the repair capacity of the bronchial epithelium of COPD subjects using the reconstituted bronchial epithelium model in air/liquid interface culture and the iPS model.
Percentage of repair at 24 hours post-lesion of ALI cultures vs. the same ALI cultures "grafted with iPS". This percentage will be determined by the surface area of the culture reconstructed after scratching divided by the surface area initially scratched.
Time frame: Day 1
comparison of % repair of post-scratch cultures in the presence or absence of IPS between the 3 groups
Calculation of the percentage of repair at 48 hours, 72 hours and at 7 days post-scratch. This percentage will be determined by the surface area of the culture rebuilt after scratching divided by the surface area initially scratched.
Time frame: Day 2, Day 3 and day 7
Comparison of transepithelial electrical resistances between groups
Verification of the integrity of the bronchial epithelium obtained by measuring the transepithelial electrical resistance. (expressed as Ω/cm2 at each time point).
Time frame: Day 2, Day 3 and day 7
Determining the proportion of GFP-tagged iPS cells vs. native cells in lesion repair:
Cell density measurements (% GFP cells/total cells) by microscopy at each time point
Time frame: Day 2, Day 3 and day 7
Phenotyping of native and GFP+ iPS populations by immunofluorescent labeling of different cell types (ciliated cells, mucus cells, club cells, basal cells)
immunofluorescence will be used to assess the density of basal, club, ciliated and caliciform cells; the release of key proinflammatory cytokines classically implicated in COPD will be assayed in the supernatant of these cultures.
Time frame: Day 2, Day 3 and day 7
Comparison of the transcriptomic profile for each cell subtype obtained after sorting native cells and GFP+ iPS cells by flow cytometry.
Comparison of the transcriptomic profile by ANOVA analysis of the 10 most highly expressed genes between native cells and IPS cells.
Time frame: Day 2, Day 3 and day 7
Comparison of transcriptomic profile between ungrafted and grafted ALI.
Comparison of the transcriptomic profile by ANOVA analysis of the 10 most highly expressed genes
Time frame: Day 2, Day 3 and day 7
ciliated cell/caliciform ratio to check whether the deficient club cell subtype is restored by this technique
the ciliated cell/caliciform ratio
Time frame: Day 2, Day 3 and day 7
Plan to share: Undecided
No publications or documents are linked to this record.
Started Feb 2025 (actual). Primary completion is estimated for Jan 2028, 34 months after the start.
Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 34 months is above that.
Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
University Hospital, Montpellier →